General Information of Drug (ID: DME4856)

Drug Name
2-amino-quinoline-3-carboxylic acid amide Drug Info
Synonyms
2-aminoquinoline-3-carboxamide; 31407-28-0; 3-Quinolinecarboxamide, 2-amino-; 2-amino-quinoline-3-carboxylic acid amide; 2-amino-3-quinolinecarboxamide; CHEMBL206956; GXZOXGRLLFZVGF-UHFFFAOYSA-N; ZERO/004541; AC1NP94V; SCHEMBL30837; CTK7D2638; MolPort-002-742-881; ZX-AN021879; ALBB-023365; STK735522; BDBM50186621; SBB012747; ZINC19890815; FCH854771; AKOS003368785; MCULE-6676169786; NCGC00340196-01; 2-Aminoquinoline-3-carboxylic acid amide; OR346178; KB-118564; 2-amino-3-quinolinecarboxamide, AldrichCPR; ST4128359; R9463
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5200228
CAS Number
CAS 31407-28-0
TTD Drug ID
DME4856

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [2]
Parthenolide DMCQBFT N. A. N. A. Phase 2 [3]
SAR-113945 DMMCA9V Osteoarthritis FA00-FA05 Phase 2 [4]
IMD-1041 DMU1MR9 Alzheimer disease 8A20 Phase 2 [5]
IMD-0354 DMOFSLE Acne vulgaris ED80 Phase 1 [6]
MLN0415 DMG72VK Arthritis FA20 Discontinued in Phase 1 [7]
PF-228 DM32FKD Discovery agent N.A. Investigative [8]
5-Bromo-6-methoxy-9H-beta-carboline DM157OQ Discovery agent N.A. Investigative [9]
Staurosporine DM0E9BR Discovery agent N.A. Investigative [10]
5-amino-2-phenyl-oxazole-4-carboxylic acid amide DMX37ZC Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Inhibitor of nuclear factor kappa-B kinase beta (IKKB) TTJ3E9X IKKB_HUMAN Inhibitor [1]

References

1 Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908.
2 How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2002 Sep;2(9):705-13.
3 The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol. 2001 Aug;8(8):759-66.
4 The NF B pathway: a therapeutic target in glioblastoma. Oncotarget. 2011 August; 2(8): 646-653.
5 Inhibition of I B phosphorylation prevents load-induced cardiac dysfunction in mice. Am J Physiol Heart Circ Physiol. 2012 Dec 15;303(12):H1435-45.
6 I B kinase beta inhibitor IMD-0354 suppresses airway remodelling in a Dermatophagoides pteronyssinus-sensitized mouse model of chronic asthma. Clin Exp Allergy. 2011 Jan;41(1):104-15.
7 Company report (Millennium)
8 Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52.
9 Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2419-22.
10 UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst. 1996 Jul 17;88(14):956-65.